Literature DB >> 25684108

Autologous c-Kit+ Mesenchymal Stem Cell Injections Provide Superior Therapeutic Benefit as Compared to c-Kit+ Cardiac-Derived Stem Cells in a Feline Model of Isoproterenol-Induced Cardiomyopathy.

Sharven Taghavi1,2, Thomas E Sharp2, Jason M Duran2, Catherine A Makarewich2, Remus M Berretta2, Tim Starosta2, Hajime Kubo2, Mary Barbe3, Steven R Houser2.   

Abstract

BACKGROUND: Cardiac- (CSC) and mesenchymal-derived (MSC) CD117+ isolated stem cells improve cardiac function after injury. However, no study has compared the therapeutic benefit of these cells when used autologously.
METHODS: MSCs and CSCs were isolated on day 0. Cardiomyopathy was induced (day 28) by infusion of L-isoproterenol (1,100 ug/kg/hour) from Alzet minipumps for 10 days. Bromodeoxyuridine (BrdU) was infused via minipumps (50 mg/mL) to identify proliferative cells during the injury phase. Following injury (day 38), autologous CSC (n = 7) and MSC (n = 4) were delivered by intracoronary injection. These animals were compared to those receiving sham injections by echocardiography, invasive hemodynamics, and immunohistochemistry.
RESULTS: Fractional shortening improved with CSC (26.9 ± 1.1% vs. 16.1 ± 0.2%, p = 0.01) and MSC (25.1 ± 0.2% vs. 12.1 ± 0.5%, p = 0.01) as compared to shams. MSC were superior to CSC in improving left ventricle end-diastolic (LVED) volume (37.7 ± 3.1% vs. 19.9 ± 9.4%, p = 0.03) and ejection fraction (27.7 ± 0.1% vs. 19.9 ± 0.4%, p = 0.02). LVED pressure was less in MSC (6.3 ± 1.3 mmHg) as compared to CSC (9.3 ± 0.7 mmHg) and sham (13.3 ± 0.7); p = 0.01. LV BrdU+ myocytes were higher in MSC (0.17 ± 0.03%) than CSC (0.09 ± 0.01%) and sham (0.06 ± 01%); p < 0.001.
CONCLUSIONS: Both CD117+ isolated CSC and MSC therapy improve cardiac function and attenuate pathological remodeling. However, MSC appear to confer additional benefit.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiomyopathy; cardiovascular diseases; heart failure

Mesh:

Substances:

Year:  2015        PMID: 25684108      PMCID: PMC5351102          DOI: 10.1111/cts.12251

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  57 in total

1.  Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

Authors:  David M Leistner; Ulrich Fischer-Rasokat; Jörg Honold; Florian H Seeger; Volker Schächinger; Ralf Lehmann; Hans Martin; Iris Burck; Carmen Urbich; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

2.  Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study.

Authors:  Remco Koninckx; Annick Daniëls; Severina Windmolders; Françoise Carlotti; Urbain Mees; Paul Steels; Jean-Luc Rummens; Marc Hendrikx; Karen Hensen
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

Review 3.  Ventricular myocytes are not terminally differentiated in the adult mammalian heart.

Authors:  P Anversa; J Kajstura
Journal:  Circ Res       Date:  1998-07-13       Impact factor: 17.367

4.  Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors:  Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

5.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

6.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival.

Authors:  D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

7.  Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Nikos Werner; Jürgen Haase; Jörg Neuzner; Alfried Germing; Bernd Mark; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Eur Heart J       Date:  2006-11-10       Impact factor: 29.983

8.  Stem cell therapy for heart failure.

Authors:  David Angert; Steven R Houser
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

Review 9.  Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review.

Authors:  Enca Martin-Rendon; Susan J Brunskill; Chris J Hyde; Simon J Stanworth; Anthony Mathur; Suzanne M Watt
Journal:  Eur Heart J       Date:  2008-06-03       Impact factor: 29.983

Review 10.  Paracrine mechanisms in adult stem cell signaling and therapy.

Authors:  Massimiliano Gnecchi; Zhiping Zhang; Aiguo Ni; Victor J Dzau
Journal:  Circ Res       Date:  2008-11-21       Impact factor: 17.367

View more
  13 in total

Review 1.  "The state of the heart": Recent advances in engineering human cardiac tissue from pluripotent stem cells.

Authors:  Dario Sirabella; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-10

2.  After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease.

Authors:  Roberto Bolli; Xian-Liang Tang; Yiru Guo; Qianghong Li
Journal:  Can J Physiol Pharmacol       Date:  2020-09-16       Impact factor: 2.273

3.  In Vivo Kinetics of Mesenchymal Stem Cells Transplanted into the Knee Joint in a Rat Model Using a Novel Magnetic Method of Localization.

Authors:  Yasunari Ikuta; Naosuke Kamei; Masakazu Ishikawa; Nobuo Adachi; Mitsuo Ochi
Journal:  Clin Transl Sci       Date:  2015-05-12       Impact factor: 4.689

4.  c-kit+VEGFR-2+ Mesenchymal Stem Cells Differentiate into Cardiovascular Cells and Repair Infarcted Myocardium after Transplantation.

Authors:  Pei Zhou; Shu-Na Yu; Hai-Feng Zhang; Yong-Li Wang; Ping Tao; Yu-Zhen Tan; Hai-Jie Wang
Journal:  Stem Cell Rev Rep       Date:  2022-08-13       Impact factor: 6.692

5.  Cardiac Stem Cell Hybrids Enhance Myocardial Repair.

Authors:  Pearl Quijada; Hazel T Salunga; Nirmala Hariharan; Jonathan D Cubillo; Farid G El-Sayed; Maryam Moshref; Kristin M Bala; Jacqueline M Emathinger; Andrea De La Torre; Lucia Ormachea; Roberto Alvarez; Natalie A Gude; Mark A Sussman
Journal:  Circ Res       Date:  2015-07-30       Impact factor: 17.367

Review 6.  Empowering Adult Stem Cells for Myocardial Regeneration V2.0: Success in Small Steps.

Authors:  Kathleen M Broughton; Mark A Sussman
Journal:  Circ Res       Date:  2016-03-04       Impact factor: 17.367

7.  miR-21 Reduces Hydrogen Peroxide-Induced Apoptosis in c-kit+ Cardiac Stem Cells In Vitro through PTEN/PI3K/Akt Signaling.

Authors:  Wenwen Deng; Yan Wang; Xianping Long; Ranzun Zhao; Zhenglong Wang; Zhijiang Liu; Song Cao; Bei Shi
Journal:  Oxid Med Cell Longev       Date:  2016-10-10       Impact factor: 6.543

8.  Preconditioning Human Cardiac Stem Cells with an HO-1 Inducer Exerts Beneficial Effects After Cell Transplantation in the Infarcted Murine Heart.

Authors:  Chuanxi Cai; Yiru Guo; Lei Teng; Yibing Nong; Min Tan; Michael J Book; Xiaoping Zhu; Xiao-Liang Wang; Junjie Du; Wen-Jian Wu; Wei Xie; Kyung U Hong; Qianhong Li; Roberto Bolli
Journal:  Stem Cells       Date:  2015-09-23       Impact factor: 6.277

9.  miR-21 increases c-kit+ cardiac stem cell proliferation in vitro through PTEN/PI3K/Akt signaling.

Authors:  Bei Shi; Wenwen Deng; Xianping Long; Ranzun Zhao; Yan Wang; Wenming Chen; Guanxue Xu; Jin Sheng; Dongmei Wang; Song Cao
Journal:  PeerJ       Date:  2017-01-05       Impact factor: 2.984

10.  Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit+ cardiac stem cells from oxidative injury through the PTEN/PI3K/Akt axis.

Authors:  Bei Shi; Yan Wang; Ranzhun Zhao; Xianping Long; Wenwen Deng; Zhenglong Wang
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.